Institution
Eli Lilly and Company
Company•Indianapolis, Indiana, United States•
About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Agonist. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.
Topics: Population, Agonist, Insulin, Placebo, Olanzapine
Papers published on a yearly basis
Papers
More filters
TL;DR: The American Chemical Society (ACS) Green Chemistry Institute (GCI) and global pharmaceutical companies established the ACS GCI Pharmaceutical Roundtable to encourage the integration of green chemistry and engineering into the pharmaceutical industry as mentioned in this paper.
352 citations
TL;DR: It is shown that ADAM22, a transmembrane protein that when mutated itself causes seizure, serves as a receptor for LGI1, a secreted neuronal protein that enhances AMPA receptor-mediated synaptic transmission in hippocampal slices.
Abstract: Abnormally synchronized synaptic transmission in the brain causes epilepsy. Most inherited forms of epilepsy result from mutations in ion channels. However, one form of epilepsy, autosomal dominant partial epilepsy with auditory features (ADPEAF), is characterized by mutations in a secreted neuronal protein, LGI1. We show that ADAM22, a transmembrane protein that when mutated itself causes seizure, serves as a receptor for LGI1. LGI1 enhances AMPA receptor-mediated synaptic transmission in hippocampal slices. The mutated form of LGI1 fails to bind to ADAM22. ADAM22 is anchored to the postsynaptic density by cytoskeletal scaffolds containing stargazin. These studies in rat brain indicate possible avenues for understanding human epilepsy.
352 citations
351 citations
TL;DR: The baricitinib 4 mg dose, but not the 2mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricit inib.
350 citations
TL;DR: Tadalafil significantly improved the mean change from baseline in International Prostate Symptom Score at 6 weeks and at 12 weeks and made significant improvements in the Benign Prostatic Hyperplasia Impact Index (significant at12 weeks) vs placebo.
350 citations
Authors
Showing all 17866 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Mark J. Daly | 204 | 763 | 304452 |
| Irving L. Weissman | 201 | 1141 | 172504 |
| Eric J. Topol | 193 | 1373 | 151025 |
| Tony Hunter | 175 | 593 | 124726 |
| Xiang Zhang | 154 | 1733 | 117576 |
| Jerrold M. Olefsky | 143 | 595 | 77356 |
| Stephen F. Badylak | 133 | 530 | 57083 |
| George A. Bray | 131 | 896 | 100975 |
| Lloyd Paul Aiello | 131 | 506 | 85550 |
| Levi A. Garraway | 129 | 366 | 99989 |
| Mark Sullivan | 126 | 802 | 63916 |
| James A. Russell | 124 | 1024 | 87929 |
| Tony L. Yaksh | 123 | 806 | 60898 |
| Elisabetta Dejana | 122 | 430 | 48254 |
| Hagop S. Akiskal | 118 | 565 | 50869 |